CRISPR Therapeutics AG vs Pfizer, Inc. — Stock Comparison

CRSP
CRISPR Therapeutics AG
$51.63
▼ 1.36%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Pfizer, Inc.
PFE6.5/10vs 5.2/10

Q·Score Breakdown

5.2
Bearish
Overall
6.5
Neutral
1.6
Quality
7.4
8.7
Health
7
3.5
Growth
5.6
6.8
Valuation
6.7
6.9
Sentiment
5.2
CRSP

Clean balance sheet with low leverage (0.1× debt-to-equity).

low return on equity (-30%).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $83.35 (+61.4%)
23 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

CRSP
PFE
Trailing P/E
19.4×
-12.9×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-30.2%
ROE
8.9%
-97.6%
Revenue Growth
-1.2%
Earnings Growth
1.79
Beta
0.39
Price / Book
$5.0B
Market Cap
$149.8B
$33 – $78
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →